Literature DB >> 15738296

N-terminal-pro-brain natriuretic peptide as a haemodynamic marker in idiopathic pulmonary arterial hypertension.

R Souza1, H B Bogossian, M Humbert, C Jardim, R Rabelo, M B P Amato, C R R Carvalho.   

Abstract

Patients with idiopathic pulmonary arterial hypertension usually undergo acute vasodilator tests with nitric oxide (NO) for haemodynamic evaluation and therapeutical planning. The aim of this study was to evaluate the link between the variation of N-terminal (NT)-pro-brain natriuretic peptide (BNP) levels and haemodynamic parameters during the acute vasodilator test. A total of 22 idiopathic pulmonary arterial hypertension patients who underwent acute vasodilator tests were studied. Blood samples were collected at baseline and after 30 and 60 min of NO inhalation. NT-pro-BNP levels were measured in each sample. A receiver-operating characteristic curve was used to evaluate the capability of the NT-pro-BNP level variation during NO inhalation in recognising nonresponders. To distinguish responders from nonresponders, the increase of the NT-pro-BNP (0% as cut-off value) determined a 50% specificity and 100% sensitivity (positive predictive value of 38% and a negative predictive value of 100%). These results suggest that N-terminal-pro-brain natriuretic peptide was able to distinguish nonresponder patients with the acute vasodilator test. N-terminal-pro-brain natriuretic peptide may be an interesting additional biological tool in the evaluation of idiopathic pulmonary arterial hypertension patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15738296     DOI: 10.1183/09031936.05.00100504

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  10 in total

Review 1.  Surrogate end points in pulmonary arterial hypertension: assessing the response to therapy.

Authors:  Jennifer L Snow; Steven M Kawut
Journal:  Clin Chest Med       Date:  2007-03       Impact factor: 2.878

2.  RV Fractional Area Change and TAPSE as Predictors of Severe Right Ventricular Dysfunction in Pulmonary Hypertension: A CMR Study.

Authors:  Susana Hoette; Nicolas Creuzé; Sven Günther; David Montani; Laurent Savale; Xavier Jaïs; Florence Parent; Olivier Sitbon; Carlos Eduardo Rochitte; Gerald Simonneau; Marc Humbert; Rogerio Souza; Denis Chemla
Journal:  Lung       Date:  2018-02-12       Impact factor: 2.584

3.  Clinical and haemodynamic evaluation of chronic thromboembolic pulmonary hypertension patients scheduled for pulmonary thromboendarterectomy: Is schistosomiasis hypertension an important confounding factor?

Authors:  Mario Terra-Filho; Marcos Figueiredo Mello; Mônica Silveira Lapa; Ricardo Henrique Oliveira Braga Teixeira; Fábio Biscegli Jatene
Journal:  Clinics (Sao Paulo)       Date:  2010       Impact factor: 2.365

4.  Circulating NEDD9 is increased in pulmonary arterial hypertension: A multicenter, retrospective analysis.

Authors:  Andriy O Samokhin; Steven Hsu; Paul B Yu; Aaron B Waxman; George A Alba; Bradley M Wertheim; C Danielle Hopkins; Frederick Bowman; Richard N Channick; Ivana Nikolic; Mariana Faria-Urbina; Paul M Hassoun; Jane A Leopold; Ryan J Tedford; Corey E Ventetuolo; Peter J Leary; Bradley A Maron
Journal:  J Heart Lung Transplant       Date:  2019-12-31       Impact factor: 10.247

5.  Prognostic Significance of Biomarkers in Pulmonary Arterial Hypertension.

Authors:  Nadine Al-Naamani; Harold I Palevsky; David J Lederer; Evelyn M Horn; Stephen C Mathai; Kari E Roberts; Russell P Tracy; Paul M Hassoun; Reda E Girgis; Daichi Shimbo; Wendy S Post; Steven M Kawut
Journal:  Ann Am Thorac Soc       Date:  2016-01

6.  The Effect of Amlodipine and Sildenafil on the NT-ProBNP Level of Patients with COPD-Induced Pulmonary Hypertension.

Authors:  Babak Sharif-Kashani; Ali Hamraghani; Jamshid Salamzadeh; Mohammad Abbasi Nazari; Majid Malekmohammad; Neda Behzadnia; Fanak Fahimi
Journal:  Iran J Pharm Res       Date:  2014       Impact factor: 1.696

7.  N-terminal pro-brain natriuretic peptide is a useful prognostic marker in patients with pre-capillary pulmonary hypertension and renal insufficiency.

Authors:  Lars Harbaum; Jan K Hennigs; Hans J Baumann; Nicole Lüneburg; Elisabeth Griesch; Carsten Bokemeyer; Ekkehard Grünig; Hans Klose
Journal:  PLoS One       Date:  2014-04-21       Impact factor: 3.240

8.  Significance of NT-pro-BNP in acute exacerbation of COPD patients without underlying left ventricular dysfunction.

Authors:  Muhammad Adrish; Varalaxmi Bhavani Nannaka; Edison J Cano; Bharat Bajantri; Gilda Diaz-Fuentes
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2017-04-13

9.  Experimental design of the Effects of Dehydroepiandrosterone in Pulmonary Hypertension (EDIPHY) trial.

Authors:  Thomas P Walsh; Grayson L Baird; Michael K Atalay; Saurabh Agarwal; Daniel Arcuri; James R Klinger; Christopher J Mullin; Heather Morreo; Brynn Normandin; Sruti Shiva; Mary Whittenhall; Corey E Ventetuolo
Journal:  Pulm Circ       Date:  2021-05-21       Impact factor: 3.017

Review 10.  Pulmonary Hypertension and Indicators of Right Ventricular Function.

Authors:  Célia von Siebenthal; John-David Aubert; Periklis Mitsakis; Patrick Yerly; John O Prior; Laurent Pierre Nicod
Journal:  Front Med (Lausanne)       Date:  2016-06-03
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.